Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Interest Expenses (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Interest Expenses for 10 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses fell 11.21% year-over-year to $1.9 million, compared with a TTM value of $8.0 million through Dec 2025, up 8.52%, and an annual FY2025 reading of $8.0 million, up 8.52% over the prior year.
  • Interest Expenses was $1.9 million for Q4 2025 at Zevra Therapeutics, down from $2.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.3 million in Q3 2024 and bottomed at $5000.0 in Q4 2021.
  • Average Interest Expenses over 5 years is $915263.2, with a median of $366000.0 recorded in 2023.
  • The sharpest move saw Interest Expenses plummeted 99.57% in 2021, then skyrocketed 3300.0% in 2022.
  • Year by year, Interest Expenses stood at $5000.0 in 2021, then surged by 3300.0% to $170000.0 in 2022, then skyrocketed by 344.71% to $756000.0 in 2023, then surged by 190.21% to $2.2 million in 2024, then decreased by 11.21% to $1.9 million in 2025.
  • Business Quant data shows Interest Expenses for ZVRA at $1.9 million in Q4 2025, $2.1 million in Q3 2025, and $2.0 million in Q2 2025.